US 12,251,411 B2
Methods of treating endometrial cancer using hemp extract
Alexandra M. Capano, Philadelphia, PA (US); Pradeep Singh Tanwar, Fletcher (AU); and Alex Nance, Georgetown, KY (US)
Assigned to Ecofibre USA Inc., Georgetown, KY (US); and The University of Newcastle, Callaghan (AU)
Filed by Ecofibre USA Inc., Georgetown, KY (US); and The University of Newcastle, Callaghan (AU)
Filed on Sep. 15, 2023, as Appl. No. 18/467,953.
Application 18/467,953 is a continuation of application No. 18/050,021, filed on Oct. 26, 2022, granted, now 11,793,847.
Claims priority of provisional application 63/263,018, filed on Oct. 26, 2021.
Claims priority of provisional application 63/263,026, filed on Oct. 26, 2021.
Claims priority of provisional application 63/263,020, filed on Oct. 26, 2021.
Prior Publication US 2024/0000876 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61K 31/01 (2006.01); A61K 31/015 (2006.01); A61K 31/045 (2006.01); A61K 31/198 (2006.01); A61K 31/216 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/352 (2006.01); A61K 31/355 (2006.01); A61K 31/395 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 36/185 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC A61K 36/185 (2013.01) [A61K 31/01 (2013.01); A61K 31/015 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/198 (2013.01); A61K 31/216 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/352 (2013.01); A61K 31/355 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/5545 (2017.08); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 18 Claims
 
1. A method for treating endometrial cancer comprising:
a. administering to a patient an effective amount of a composition comprising a cannabis extract (CE) wherein the CE comprises between 50% and 99.9% cannabidiol (CBD) and wherein said composition has a pH of between 3.5 and 6;
b. wherein the CE is administered via an intravaginal form; and
c. wherein the effective amount of the CE comprises between 10 mg and 4,250 mg of CBD per day.